- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04712877
Test af tumorvæv og -blod for at hjælpe med at vælge personlige behandlinger til patienter med mistænkt lungekræft
LEADER Neoadjuverende screeningsforsøg: LCMC4-evaluering af handlingsfremmende drivere i tidligt stadie af lungekræft
This collaborative screening protocol, developed by the Lung Cancer Mutation Consortium (LCMC) and supported by the Thoracic Surgery Oncology Group (TSOG), is designed to determine the feasibility of comprehensive molecular profiling to detect actionable oncogenic drivers in patients with suspected early stage lung cancers scheduled to undergo biopsies to establish the diagnosis of lung cancer.
The primary purpose of this testing is to determine the presence of 12 oncogenic drivers (mutations in EGFR, BRAFV600E , MET exon 14, KRAS G12C and HER2, rearrangements in ALK, RET, NTRK, EGFR exon 20 insertion and ROS1, and amplification of MET and HER2) that can serve as targets making patients eligible for upcoming targeted neoadjuvant therapy trials. The ultimate goal is to use this information from the screening process to select the optimal neoadjuvant therapy and wherever possible enroll patients onto separate neoadjuvant therapy trials with genomically matched treatments or other appropriate trials if no actionable driver mutation is detected.
Thoracic Surgery Oncology Group (TSOG) is a network of surgeons within North American Thoracic Surgery Academic Centers aligned with the goal of enhancing patient care through administration of multi-site trials focused on recent advances in lung cancer. TSOG has aligned with the LCMC4 sites to enroll the LCRF-LEADER screening trial. TSOG's involvement will be essential in trial enrollment and ultimate interpretation of the multimodal clinical and translational data collected as part of this study. We estimate we will detect an actionable oncogenic driver in 33% of cases. The remaining 66% of patients will represent a cohort identified by their care teams as candidates for other potential neoadjuvant therapies which may include checkpoint inhibitors such as atezolizumab, durvalumab, nivolumab, and pembrolizumab or other novel agents.
The targeted therapy treatment trials will be conducted independently of the LCRF-LEADER screening trial, evaluating for efficacy. If none of the 10 oncogenic drivers are detected, the patient will be offered participation in any clinical trial of neoadjuvant therapy available at their treating institution or standard of care therapy. For patients not enrolled on a targeted treatment trial, circulating tumor DNA in blood (ctDNA) will be collected at 3 time points: before neoadjuvant treatment, after neoadjuvant treatment but before surgery, and after surgery. This initiative will be correlated with various clinical outcomes. Prespecified clinical data will be collected for correlation with these circulating biomarkers.
Studieoversigt
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Christian Brodala, BBA
- Telefonnummer: 646-608-2838
- E-mail: brodalac@mskcc.org
Studiesteder
-
-
California
-
Davis, California, Forenede Stater, 95616
- Aktiv, ikke rekrutterende
- University of California, Davis
-
Los Angeles, California, Forenede Stater, 90095
- Aktiv, ikke rekrutterende
- UCLA
-
Los Angeles, California, Forenede Stater, 90033
- Trukket tilbage
- USC Norris Comprehensive Cancer Center
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- St. Joseph's Hospital Orange
-
Kontakt:
- Ron Bati
- E-mail: Ron.Bati@stjoe.org
-
Ledende efterforsker:
- Tiimothy Byun, MD
-
Stanford, California, Forenede Stater, 94305
- Rekruttering
- Stanford University
-
Kontakt:
- Debbie Bajomo
- E-mail: bajomo@stanford.edu
-
Ledende efterforsker:
- Douglas Liou, MD
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Rekruttering
- Hartford Healthcare
-
Kontakt:
- Lorin Campos
- E-mail: lorin.campos@hhchealth.org
-
Kontakt:
- Corey Glider
- E-mail: Corey.Glider@hhchealth.org
-
Ledende efterforsker:
- Brian Whang, MD, FACS
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Ledende efterforsker:
- Andreas Saltos, MD
-
Kontakt:
- Tara Ackerman
- E-mail: Tara.Ackerman@moffitt.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern University
-
Ledende efterforsker:
- Jyoti Patel, MD
-
Kontakt:
- RHLCCC Trial Team
- E-mail: RHLCCCTrialStartup@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Brigham and Women's Hospital
-
Kontakt:
- Kristina Sidopoulos
- E-mail: ksidopoulos@bwh.harvard.edu
-
Ledende efterforsker:
- Hisashi Tsukada, MD, PhD
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Ledende efterforsker:
- Michael Lanuti, MD
-
Kontakt:
- Isha Mehta Warikoo
- E-mail: imehtawarikoo@mgh.harvard.edu
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Dana-Farber Cancer Institute
-
Ledende efterforsker:
- David Kwiatkowski, MD
-
Kontakt:
- Jennifer Luu
- E-mail: jennifer_luu@dfci.harvard.edu
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Beth Israel Deaconess Medical Center
-
Kontakt:
- Christine Conley
- E-mail: Cconley@bidmc.harvard.edu
-
Ledende efterforsker:
- Sidhu Gangadharan, MD
-
Boston, Massachusetts, Forenede Stater, 02118
- Rekruttering
- Boston Medical Center
-
Kontakt:
- Anthony Shelton
- E-mail: anthony.shelton@bmc.org
-
Ledende efterforsker:
- Umit Tapan, MD
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan
-
Kontakt:
- Shari Barnett
- E-mail: shbailey@med.umich.edu
-
Ledende efterforsker:
- Jules Lin, MD
-
-
Missouri
-
Columbia, Missouri, Forenede Stater, 65212
- Rekruttering
- University of Missouri
-
Kontakt:
- Brooke McDaniel
- E-mail: mcdanielbl@health.missouri.edu
-
Ledende efterforsker:
- Jussuf Kaifi, MD
-
St Louis, Missouri, Forenede Stater, 63110
- Aktiv, ikke rekrutterende
- Washington University
-
-
New Hampshire
-
Lebanon, New Hampshire, Forenede Stater, 03756
- Rekruttering
- Dartmouth-Hitchcock
-
Kontakt:
- Kristina Wiley
- E-mail: Kristina.M.Willey@hitchcock.org
-
Ledende efterforsker:
- David Finley, MD
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Aktiv, ikke rekrutterende
- Columbia University
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- NYU
-
Ledende efterforsker:
- Elaine Shum, MD
-
Kontakt:
- Nadia Catti
- E-mail: nadia.catti@nyulangone.org
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University
-
Kontakt:
- Helena Gastier
- E-mail: Helena.gastier@osumc.edu
-
Ledende efterforsker:
- Desmond D'Souza, MD
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97213
- Rekruttering
- Providence Portland
-
Ledende efterforsker:
- Rachel Sanborn, MD
-
Kontakt:
- Brenda Fisher
- E-mail: brenda.fisher@providence.org
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Kontakt:
- Jessica Shealor
- E-mail: shealorj@musc.edu
-
Ledende efterforsker:
- Ian Bostock, MD
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Kontakt:
- Michelle Almarez
- E-mail: michelle.almarez@bcm.edu
-
Ledende efterforsker:
- Taylor Ripley, MD
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Virginia Cancer Specialists, PC
-
Ledende efterforsker:
- Alexander Spira, MD, PhD, FACP
-
Kontakt:
- Brian Phipps
- E-mail: Brian.phipps@usoncology.com
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98019
- Rekruttering
- University of Washington
-
Kontakt:
- Lara Schiff
- E-mail: lschiff1@seattlecca.org
-
Ledende efterforsker:
- Christina Baik, MD, MPH
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The LCMC LEADER screening trial will enroll all patients with clinically suspected, resectable stage I-III lung cancers. The population of interest is patients with resectable non-squamous non-small cell lung cancer, however a histologic diagnosis is not required at the time of study enrollment. We anticipate a small portion of patients with squamous cell and non-NSCLC histologies to be genotyped centrally in parallel to their histologic diagnosis. Only patients with non-small cell lung cancers that are not purely squamous will be counted towards the primary study endpoint.
Beskrivelse
Inclusion Criteria:
- Clinical stage IA2-III lung cancers
- Potentially resectable if lung cancer suspicion confirmed pathologically
- Operable
Exclusion Criteria:
- No concurrent malignancy
- No prior lung cancer within last 2 years
- Purely ground glass pulmonary opacity
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Patients who Possess Actionable Oncogenic Drivers
Tidsramme: 8 weeks
|
The primary outcome measure is the determination of the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. A patient is considered to have a actionable oncogenic driver if they have any of the following 10 genomic alterations: ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, or ROS1 rearrangements. |
8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Tumor Mutation Burden (TMB) Assessment
Tidsramme: 8 weeks
|
Measure TMB in all patient tumor samples (Mutations per megabase) |
8 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Michael Lanuti, MD, Massachusetts General Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- LCMC LEADER
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .